Trial Profile
The efficiency of recombinant human erythropoietin in reducing the need for blood transfusions in patients with solid tumors receiving chemotherapy.
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 21 Sep 2016
Price :
$35
*
At a glance
- Drugs Erythropoietin (Primary)
- Indications Anaemia
- Focus Therapeutic Use
- 21 Sep 2016 New trial record